<DOC>
	<DOC>NCT02881034</DOC>
	<brief_summary>Anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin than in those receiving pegylated-interferon/ribavirin alone. The objective was to measure the impact of telaprevir on ribavirin bioavailability and to assess the concomitant renal function.</brief_summary>
	<brief_title>Ribavirin Bioavailability After Telaprevir Exposure</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Patients with hepatitis C virus infection Previous nonresponse to pegylatedinterferon/ribavirin therapy Retreatment with pegylatedinterferon/ribavirin and telaprevir Decompensated liver cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Glomerular Filtration Rate</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Telaprevir</keyword>
</DOC>